Statement on the benefit assessment of trastuzumab deruxtecan (adenocarcinoma of the stomach or gastroesophageal junction, HER2-positive) of May 23, 2023

被引：0
|
作者：
不详
机构：
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2023年 / 61卷 / 07期
关键词：
D O I：
10.1055/a-2110-6846
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：938 / 942
页数：5
相关论文
共 50 条
  • [21] Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?
    Roodhart, Jeanine M. L.
    Koopman, Miriam
    LANCET ONCOLOGY, 2024, 25 (09): : 1104 - 1105
  • [22] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Tina Nie
    Hannah A. Blair
    Targeted Oncology, 2023, 18 : 463 - 470
  • [23] Trastuzumab deruxtecan in previously treated advanced HER2-positive gastric cancer
    Pamuk, Aylin
    Kuetting, Fabian
    Alakus, Hakan
    Bruns, Christiane
    ONKOLOGE, 2021, 27 (01): : 74 - 76
  • [24] A phase II trial of [fam-] trastuzumab deruxtecan (T-DXd, DS-8201a) in subjects with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Fuchs, Charles S.
    Shahidi, Javad
    Mathew, Lijoy
    Qin, Amy
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [25] Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
    Iwata, Hiroji
    Xu, Binghe
    Kim, Sung-Bae
    Chung, Wei-Pang
    Park, Yeon Hee
    Kim, Min Hwan
    Tseng, Ling-Ming
    Chung, Chi-Feng
    Huang, Chiun-Sheng
    Kim, Jee Hyun
    Chiu, Joanne Wing Yan
    Yamashita, Toshinari
    Li, Wei
    Egorov, Anton
    Nishijima, Soichiro
    Nakatani, Shunsuke
    Nishiyama, Yuji
    Sugihara, Masahiro
    Cortes, Javier
    Im, Seock-Ah
    CANCER SCIENCE, 2024, 115 (09) : 3079 - 3088
  • [26] Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective
    Masahiko Aoki
    Satoru Iwasa
    Narikazu Boku
    Gastric Cancer, 2021, 24 : 567 - 576
  • [27] Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective
    Aoki, Masahiko
    Iwasa, Satoru
    Boku, Narikazu
    GASTRIC CANCER, 2021, 24 (03) : 567 - 576
  • [28] Safety of trastuzumab deruxtecan and radiation therapy in HER2-positive breast cancer patients
    Visani, Luca
    Ratosa, Ivica
    Ribnikar, Domen
    Becherini, Carlotta
    Bertini, Niccolo
    Bonaparte, Ilaria
    Stefanovski, Dimitar
    Dobnikar, Nika
    Desideri, Isacco
    Olmetto, Emanuela
    Mangoni, Monica
    Di Cataldo, Vanessa
    Peruzzi, Anna
    Mattioli, Chiara
    Cela, Doruntina
    Valzano, Marianna
    Salvestrini, Viola
    Scoccimarro, Erika
    Livi, Lorenzo
    Meattini, Icro
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S691 - S692
  • [29] Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer
    Bartsch, Rupert
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (09) : 901 - 910
  • [30] Trastuzumab Deruxtecan for HER2-Positive Breast Cancer with Central Nervous System Metastasis
    Yamane, Hiroaki
    Itagaki, Tomoko
    Kajitani, Keiko
    CASE REPORTS IN ONCOLOGY, 2025, 18 (01): : 22 - 28
12345